VICE Media has created a new distribution platform for premium online video content, digital publishers and audiences, using Ooyala video solutions to stream video content across all devices.

The “VICE Player” will tailor editorially relevant content to the best-suited digital publishers and platforms, sharing VICE’s 300+ hours of premium, original video content with thousands of global publishing partners through its AdVICE network.

Both publisher partners, as well as global video rights holders, will be able to utilise the VICE Player’s customizable technology and the network’s global reach to distribute and monetise content.

“Premium video content is shaping the way that consumers engage with news, entertainment, informing opinions and lifestyle choices more than ever,” said Dan’l Hewitt, General Manager for AdVICE. “There is no question that audience demand continues to outpace output online”

The platform will put video advertising messages into places and in front of audiences that they have not been before and
distribute branded video across leading platforms including Facebook, Twitter and mobile applications.

VICE Media is a leading global youth media company operating in over 34 countries, and includes the world’s premier original online video destination, VICE.COM.

The post Vice Media and Ooyala Launch new Premium Online Video Platform appeared first on Ropart Asset Management.

SOUTHAMPTON, Pa. — QC Laboratories (QCL), a leader in providing microbiology and analytical chemistry services to the food, pharmaceutical and dairy industries is pleased to announce that Crispin Philpot has joined the organization as Director of Business Development & Sales of the Life Sciences Division. The addition of Mr. Philpott will enable QCL to focus sales and marketing activities for Life Sciences and establish the strategic direction for the growth of the division.

Crispin has over 25 years of leadership experience in the sales and marketing of Quality Assurance and Food Safety diagnostic solutions to the global food industry, and has held senior staff positions focusing on sales, marketing and strategic development in several major organizations. He brings a deep knowledge of Food Safety and Quality challenges and regulatory requirements to the Company. Crispin is a past Committee Chair within the International Association for Food Protection (IAFP), member of the Beef Industry Food Safety Council (BIFSCO), a contributor to Food Safety magazine and former consultant on emerging diagnostic technologies within embryonic companies.

David Speis, Chief Executive Officer of QCL said, “The addition of Crispin Philpott will be a tremendous boost to QCL’s Life Sciences business development and sales efforts. I am extremely pleased to bring a seasoned professional of Crispin’s caliber into the organization.

About QC Laboratories. QCL has provided analytical services to environmental, food, pharmaceutical and dairy clients in Pennsylvania, New Jersey, New York, Delaware and Maryland since its establishment in 1943. The company currently employs over 200 professional scientists and support personnel and operates eight facilities in Pennsylvania, New Jersey and Delaware. Life Sciences operations are conducted from a state-of-the-art 25,000 square foot facility in Horsham, Pennsylvania. Environmental analysis is conducted from a 35,000 square foot facility in Southampton, Pennsylvania. The Company also operates satellite facilities in Wind Gap and Reading, Pennsylvania; Vineland and East Rutherford, New Jersey and a limited services environmental laboratory in New Castle, Delaware.

For further information please contact Bill Coer, Chief Financial Officer for QCL at 215.355.3900 ex 4304 or wcoer@qclaboratories.com or visit us at www.qclaboratories.com.

QCL
Bill Coer, Chief Financial Officer
215-355-3900 ex 4304
wcoer@qclaboratories.com

The post Crispin Philpott Joins QC Laboratories as Director of Business Development & Sales – Life Sciences Division appeared first on Ropart Asset Management.

Meriden, CT February 20, 2013

Protein Sciences Corporation announced today that Wayne Hachey, DO (Colonel, U.S. Army, ret.) has joined the Company’s management as Head, Government and Clinical Affairs. Dr. Hachey is a physician who has dedicated 28 years of service to the military healthcare system, including six years as a subject matter expert advising senior Department of Defense (DoD) leadership regarding the DoD’s vaccine policy. He was also responsible for developing the overarching DoD mitigation response to pandemic influenza and directed the implementation of that policy during the 2009 H1N1 pandemic. Most recently, Dr. Hachey served as the Chief of Public Health for the 1st Medical Brigade in Afghanistan where he provided public health leadership to protect over 98,000 U.S. troops. He is board certified in Public Health, Pediatrics and Neonatal-Perinatal Medicine and has won numerous awards, including the Defense Meritorious Service Medal, Meritorious Service Medal, NATO (Afghanistan) and Afghanistan Campaign Medal and Unit Combat Patch.

Dr. Manon Cox, MBA, President and CEO of Protein Sciences commented, “We are delighted to welcome Dr. Hachey to our team.” She added, “In his new role, his primary responsibility will be to play a key role in our Company’s interactions with government agencies.”

Dr. Hachey will represent Protein Sciences at the following meetings this week where the Company’s revolutionary new influenza vaccine Flublok® will be presented:

The Advisory Committee on Immunization Practices (ACIP) Meeting:

About Us

Protein Sciences Corporation is a vaccine development and protein production company based in Meriden, CT that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceuticals. Our proprietary baculovirus expression vector system (BEVS) technology provides a fast, reliable and inexpensive platform for the production

of high quality recombinant proteins, making it a powerful tool for producing vaccines and therapeutics when they are needed most. BEVS technology is covered by broad patents that include our proprietary expresSF+® cell line that we use to make all of our products.

On January 16, the FDA approved Flublok, a novel influenza vaccine for the prevention of influenza in adults aged 18-49 years old. The FDA has called Flublok a revolutionary vaccine as no eggs or live influenza virus is used in its manufacturing process. In addition, the product does not contain a preservative (e.g., thimerosal), latex, adjuvants or other additives.

Learn more at www.proteinsciences.com and www.flublok.com.

The post Dr. Wayne Hachey Joins Protein Sciences’ Leadership appeared first on Ropart Asset Management.

February 15, 2013

At a press conference today showcasing Protein Sciences’ newly leased manufacturing facility for Flublok, the Company announced that the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, will continue to support the Company’s influenza vaccines program. BARDA held an internal review of the Protein Sciences program and made a decision to modify its contract with the Company to support certain activities associated with scaling up manufacturing to meet the capacity metrics in the contract and to be able to expand the age indication of Flublok and Panblok influenza vaccines. Flublok is a revolutionary new seasonal influenza vaccine that was granted U.S. FDA approval in January for use in adults 18-49 years old. The Company expects to have approval for use of Flublok in people 50 years and above in time for the 2013/14 influenza season. Flublok’s sister vaccine, Panblok, is being developed to protect against pandemic influenza. Protein Sciences and BARDA entered negotiations to provide additional support for the establishment of Flublok large-scale manufacturing in Pearl River, NY and help fund clinical studies required to secure FDA approval of Flublok for use in populations not included in the initial approval. Thirteen new employees have already been hired to begin operations in Pearl River, and the Company plans to add approximately 30 more within the next year.

“We are pleased that BARDA has continued their commitment to support our influenza vaccine program,” said Manon Cox, CEO of Protein Sciences. “We could not have brought Flublok to market without their support, and their continued commitment will enable us to provide more doses of this important vaccine to more people in less time and to develop Panblok as an effective vaccine against pandemic influenza.”

Flublok and Panblok are the world’s first recombinant vaccines for the prevention of influenza. They are made using Protein Sciences’ egg-free BEVS technology, a platform that enables rapid production of vaccine without the use of live influenza virus, an important feature in the face of a pandemic. Protein Sciences’ Pearl River facility will enable large-scale production of either vaccine depending on need.

Today’s conference marked one of the first occasions where Flublok was available for immunization of the public.

Learn more at www.proteinsciences.com and www.flublok.com.

The post BARDA Continues Support of Flublok® and Panblok® appeared first on Ropart Asset Management.

MERIDEN, Conn., Jan. 16, 2013

• The U.S. FDA approved Flublok for people 18-49 years old – making it the first recombinant vaccine for influenza available on the market. Approval for all people 18 years and above is expected later in 2013.

• Flublok features:
  • First influenza vaccine made without the use of live influenza virus
  • First egg-free influenza vaccine
  • Highly purified without preservatives (thimerosal), antibiotics or adjuvants
  • Three times the active ingredient in traditional influenza vaccines
  • Manufactured in a fraction of the time required for traditional influenza vaccines

Protein Sciences Corporation announced today that the U.S. Food and Drug Administration (FDA) approved Flublok influenza vaccine for use in people 18-49 years old.

Flublok is a novel protein vaccine for the prevention of seasonal influenza disease and is the first to be made in a 100% egg-free system without growing influenza viruses – so the vaccine can be made quickly and without any of the infectious risk traditionally associated with vaccine manufacture.  Flublok is highly purified, has three times the amount of active ingredient in traditional influenza vaccines, and contains no preservatives (thimerosal), antibiotics or adjuvants.

“Flublok is truly a modern vaccine,” said Manon Cox, CEO of Protein Sciences.  She explained, “We use advanced scientific technology to make just the active ingredient of the vaccine without any other viral components.  This is the first influenza vaccine on the market to do so.”

Flublok and its sister vaccine, Panblok®, that is designed to protect against pandemic influenza, have been developed in partnership with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, through Contract No. HHS0100200900106C that was awarded in 2009.  Early clinical development of Flublok and Panblok was supported by generous grants from the National Institutes of Health through the Vaccine Treatment and Evaluation Units.

Flublok will be widely available for the 2013-2014 influenza season and is available in limited supply for the current season.  Additional information about Flublok including patient information and announcements regarding where to get the vaccine can be found at www.flublok.com.  Please refer to the complete Flublok package insert available on the website for full prescribing information.

Flublok is a trivalent composition of recombinant influenza hemagglutinin (rHA) proteins that are manufactured using Protein Sciences’ proprietary baculovirus expression vector system (BEVS) technology and expresSF+® cell line.

About Us

Protein Sciences Corporation is a vaccine development and protein production company based in Meriden, CTthat is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceu­ticals. Our proprietary BEVS technology provides a fast, reliable and inexpensive platform for the production of high quality recombinant proteins, making it a powerful tool for producing vaccines and therapeutics when they are needed most.  BEVS technology is covered by broad patents that include our proprietaryexpresSF+® cell line that we use to make all of our products.

We recently expanded to Pearl River, NY where we will manufacture Flublok in addition to our Meriden, CT facility.

CONTACT: Manon Cox, President & CEO, +1-203-686-0800 ext. 308

###

The post U.S. FDA Approves Flublok®, the World’s First Recombinant, Highly Purified, Egg-Free Influenza Vaccine appeared first on Ropart Asset Management.

Prior to joining Ropart, he worked in the Mergers and Acquisitions Investment Banking group of Jefferies & Company. While at Jefferies & Company, he focused on transactions in the healthcare, industrial, consumer & retail, and business services industries. His experience entailed both buy side and sell side engagements as well as distressed and special situations transactions.

Mr. Khalil received a BBA with a concentration in Finance from the Stephen M. Ross School of Business at the University of Michigan.

About The Ropart Asset Management Funds
The Ropart Asset Management Funds (“RAM”) is a private equity firm that invests directly in small to midsize companies. The firm pursues a flexible strategy, investing throughout the capital structure and in multiple industries, including business services, software/technology, consumer products, financial services, and healthcare services. The current portfolio is composed of platform/control investments, mezzanine lending, and growth capital investments. RAM generally seeks to invest $3-10 million of equity in deals but has and will participate in larger deals. RAM is active in many of its investments and generally takes a minimum of one board seat at each portfolio company.

The post Mohammed A. Khalil joins Ropart Asset Management as an Associate appeared first on Ropart Asset Management.

GREENWICH, Conn., Dec. 18, 2012 /PRNewswire/ — Blyth, Inc. (NYSE: BTH), a direct to consumer company and leading designer and marketer of candles, accessories for the home, and health and wellness products sold through the direct selling and direct marketing channels, today announced that it and the other members of ViSalus have reached an agreement whereby Blyth increased its ownership in ViSalus to more than 80% for a payment of $57.4 million to the other members of ViSalus. In addition, the other members of ViSalus have agreed to exchange their membership interests for capital stock of ViSalus, Inc. which will be redeemable in December 2017 for a total redemption price of $147.5 million. ViSalus will also redeem in January 2013 all of the outstanding interests under its Equity Incentive Plan for $25.3 million, which will be funded by Blyth.

The new agreement between Blyth and the other members of ViSalus provides for a series of transactions, detailed below, that achieve the mutually-shared objectives of providing ViSalus’ Founders and its management team the opportunity to participate in ViSalus’ future results through their ongoing ownership and participation in a new management incentive plan. In addition, the new agreement should improve Blyth’s long-term liquidity by providing for a redemption of the ViSalus stock it does not own in December 2017. All of the members of ViSalus agreed to sell their interests in ViSalus ratably, allowing Blyth to achieve an ownership position in excess of 80%.

Commenting on the execution of this definitive agreement between Blyth and the other members of ViSalus, including all of the Founders, Robert B. Goergen , Chairman and Chief Executive Officer of Blyth said, “We are extremely pleased to have crafted an agreement that meets our objectives of providing the ViSalus Founders and other members of their management team with an equity participation in ViSalus’ future results. Moreover, as a group, the ViSalus Founders continue to be significant Blyth shareholders, strengthening further this alignment. I look forward to working with Ryan and his management team to grow the ViSalus business together, making ViSalus a worldwide household brand synonymous with ‘healthy lifestyle.’”

Ryan Blair , ViSalus’ Chief Executive Officer, echoed Mr. Goergen’s comments, adding, “Nick, Blake and I are especially pleased to have finalized an agreement that demonstrates our full commitment to the global growth of ViSalus and the opportunity for our Promoters and customers to make an impact on the worldwide obesity epidemic. Our goal is to make ViSalus a household brand by providing a simple, social and achievable method for our customers to reach their health and fitness objectives.”

Mr. Blair continued, “Today’s agreement also highlights the ViSalus/Blyth partnership. We have worked with Blyth for five years now and we plan to work with them for many more.”

The new agreement between Blyth and the other members of ViSalus provides for the following transactions. The transactions between Blyth and ViSalus involve related parties as described below.

• Blyth purchased 7.6% of the membership interests of ViSalus Holdings, LLC from the other members for $57.4 million, which increased Blyth’s membership interest in ViSalus Holdings, LLC to 80.4%.
• Blyth and the other members in ViSalus Holdings, LLC exchanged their membership interests in ViSalus Holdings, LLC for common stock of ViSalus, Inc., a Nevada corporation that was a wholly-owned subsidiary of ViSalus Holdings, LLC.
• Blyth exchanged its membership interests for shares of Class A and Class B Common Stock of ViSalus, Inc. that together represent 80.4% of the capital stock of ViSalus, Inc. on a fully converted basis. Each share of Class A Common Stock entitles Blyth to one vote and each share of Class B Common Stock entitles Blyth to 10 votes on all matters submitted to ViSalus’ stockholders.
• Ryan Blair , Blake Mallen and Nick Sarnicola (ViSalus’ Founders) exchanged their membership interests in ViSalus Holdings, LLC for shares of Series B Preferred Stock of ViSalus, Inc., which together represent 13.7% of the capital stock of ViSalus, Inc. on a fully converted basis. Each share of Series B Preferred Stock entitles its holder to 10 votes on all matters submitted to ViSalus’ stockholders.
• Robert B. Goergen , Robert B. Goergen, Jr. , Todd A. Goergen (all three of whom are related parties of Blyth) and the other holders of preferred membership interests in ViSalus Holdings, LLC exchanged their preferred membership interests in ViSalus Holdings, LLC for shares of Series B Preferred Stock of ViSalus, Inc., which together represent 2.9% of the capital stock of ViSalus, Inc. on a fully converted basis.
• The remaining holders of common membership interests of ViSalus Holdings, LLC exchanged those interests for shares of Series A Preferred Stock of ViSalus, Inc., which together represent 3.0% of the capital stock of ViSalus, Inc. on a fully converted basis. Each share of Series A Preferred Stock entitles its holder to one vote on all matters submitted to ViSalus’ stockholders.
• Blyth and ViSalus have agreed to redeem all of the Series A and Series B Preferred Stock on December 31, 2017 for a total redemption price of $147.5 million, provided that the Preferred Stock shall not have converted earlier into common stock of ViSalus, Inc. as described below.
• In the event that ViSalus, Inc. completes an initial public offering that implies a valuation of at least $800 million or that has been approved by a majority of the voting power of the Preferred Stock prior to December 31, 2017, the Series A and Series B Preferred Stock will convert into Class A and Class B Common Stock, respectively, in an amount equal to their ownership percentage. The Class A Common Stock will entitle its holders to one vote and the Class B Common Stock will entitle its holders to ten votes on all matters submitted to stockholders. The implied valuation set forth in the first sentence is an aspirational goal and should not be considered the valuation of ViSalus at the date hereof or to predict ViSalus’ valuation at any time in the future.
• ViSalus will redeem all of the outstanding interests under its Equity Incentive Plan for $25.3 million, which will terminate the EIP. Blyth will provide the funds to ViSalus for this redemption.
• ViSalus will adopt a dividend policy pursuant to which it intends to pay regular cash dividends to its stockholders, subject to the prior approval by its and Blyth’s boards of directors. Based on the current ownership structure, Blyth will receive 80.4% of such dividends when and as declared and paid by ViSalus.

In addition, ViSalus is entering into new five-year employment agreements with Ryan Blair , ViSalus’ Chief Executive Officer, and Blake Mallen , its Chief Marketing Officer. ViSalus also intends to create a management incentive plan and to issue stock options and restricted stock units that will vest over an eight-year period to Mr. Blair, Mr. Mallen and ViSalus’ third Founder, Nick Sarnicola , Global Ambassador. ViSalus also intends to issue stock options and restricted stock units to its senior management team that will vest over a three-year period.

As noted above, the transactions between Blyth and ViSalus involve related parties. Robert B. Goergen (Blyth’s Chairman of the Board of Directors and Chief Executive Officer), Robert B. Goergen, Jr. (Blyth’s President and Chief Operating Officer) and Todd A. Goergen (Chief Strategy Officer of ViSalus) owned 2.4%, 0.1% and 0.8%, respectively, of the membership interests of ViSalus Holdings, LLC before the completion of the transactions described above and now own 1.8%, 0.1% and 0.6%, respectively, of the outstanding capital stock of ViSalus, Inc. Of the $57.4 million that was paid by Blyth to the other members of ViSalus, Blyth paid $5.1 million to Robert B. Goergen , $1.7 million to Todd A. Goergen (and trusts affiliated with him) and $0.2 million to Robert B. Goergen, Jr. Of the $147.5 million aggregate redemption amount of Preferred Stock that was issued by ViSalus, Inc., shares with a $13.2 million redemption amount were issued to Robert B. Goergen , shares with a $4.5 million redemption amount were issued to Todd A. Goergen (and trusts affiliated with him) and shares with a $0.5 million redemption amount were issued to Robert B. Goergen, Jr. In addition, Robert B. Goergen will receive 1.8%, Todd A. Goergen (and trusts affiliated with him) will receive 0.6% and Robert B. Goergen, Jr. will receive 0.1% of any cash dividends declared and paid by ViSalus, Inc. Robert B. Goergen is the father of Robert B. Goergen, Jr. and Todd A. Goergen , who are brothers. Pamela M. Goergen , a Director of Blyth, is the wife of Robert B. Goergen and the mother of Robert B. Goergen, Jr. and Todd A. Goergen .

Blyth, Inc., headquartered in Greenwich, CT, USA, is a direct to consumer business focused on both the direct selling and direct marketing channels. It designs and markets home fragrance products and decorative accessories, as well as weight management products, nutritional supplements and energy drink mixes. These products are sold through Direct Selling under both the home party plan and network marketing methods. The Company also designs and markets household convenience items and personalized gifts through the catalog/Internet channel. The Company manufactures most of its candles and sources nearly all of its other products. Its products are sold direct to the consumer in North America under the PartyLite®, Two Sisters Gourmet® by PartyLite and ViSalus Sciences® brands, and to consumers in the catalog/Internet channel under the As We Change®, Miles Kimball®, Exposures®, Walter Drake® and Easy Comforts® brands. In Europe, Blyth’s products are also sold under the PartyLite brand.

Blyth, Inc. may be found on the Internet at www.blyth.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the payment to be made by Blyth to the other stockholders of ViSalus in December 2017, Blyth’s long-term liquidity, ViSalus’ intention to redeem and terminate its Equity Incentive Plan, ViSalus’ intention and ability to pay cash dividends, ViSalus’ intention to enter into employment agreements with Ryan Blair and Blake Mallen , ViSalus’ intention to adopt a management incentive plan and to issue stock options and restricted stock units thereunder, and ViSalus’ ability to conduct an initial public offering, as well as any implied value of ViSalus at the time of any initial public offering. Forward-looking statements also include statements concerning our and ViSalus’ plans, objectives, goals, strategies, future events, performance or future value and underlying assumptions and other statements that are other than statements of historical facts and may be identified by words such as “will,” “expect” or “intend” and any other similar words. Actual results could differ materially due to various factors, including Blyth’s long-term liquidity and ability to make the payment to the other stockholders of ViSalus in the amount of $147.5 million in December 2017, the ability of ViSalus to conduct an initial public offering, the ability of ViSalus to enter into employment agreements with Mr. Blair and Mr. Mallen, the slowing of the United States or European economies or retail environments, the risk that we will be unable to maintain our historic growth rate, our ability to respond appropriately to changes in product demand, the risk that we will be unable to integrate the businesses that we acquire, including if we complete the acquisition of ViSalus, into our existing operations, the risks (including foreign currency fluctuations, economic and political instability, transportation delays, difficulty in maintaining quality control, trade and foreign tax laws and others) associated with international sales and foreign sourced products, risks associated with our ability to recruit new independent sales consultants, our dependence on key corporate management personnel, risks associated with the sourcing of raw materials for our products, competition in terms of price and new product introductions, risks associated with our information technology systems (including, susceptibility to outages due to fire, floods, power loss, telecommunications failures, computer viruses, break-ins and similar events) and other factors described in this press release and in the Company’s most recently filed Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. The forward-looking statements made in this press release are made only as of the date of this release, and Blyth undertakes no obligation to update them to reflect subsequent events or circumstances except as may be required by securities laws.

SOURCE Blyth, Inc.

RELATED LINKS http://www.blyth.com PR Newswire (http://s.tt/1xkFz)

The post Blyth, Inc. and ViSalus Founders Execute New Agreement appeared first on Ropart Asset Management.

Online video analytics company Ooyala has closed its Series E financing round with investments from Singapore-based investment firm EDBI, Australian telecom companyTelstra and other unnamed investors. The total amount raised is $35 million. Ooyala has operations in Singapore and Mountain View, Calif.

The post Ooyala Completes Series E Funding with Investment Firm EDBI, Establishes APAC Digital Broadcast Operations Hub in Singapore appeared first on Ropart Asset Management.

The number of shares to be offered and the price range for the offering have not yet been determined. A portion of the shares to be offered in the IPO will be issued and sold by ViSalus, and a portion will be sold by certain stockholders of ViSalus. ViSalus is a majority-owned subsidiary of Blyth, Inc. (NYSE: BTH). Blyth will continue to own over 50% of ViSalus’ common stock following the IPO.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”), and is available on the SEC’s website at www.sec.gov, but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted before the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Jefferies & Company, Inc. will act as book-running manager for the offering. The initial public offering will be made only by means of a written prospectus meeting the requirements of Section 10 of the Securities Act of 1933. When available, a copy of the prospectus may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by email atProspectus_Department@Jefferies.com, or by telephone at +1-877-547-6340.
###

Contact: Katie Turner, ICR
katie.turner@icrinc.com, +1-914-364-1567

The post ViSalus Files Registration Statement for Initial Public Offering appeared first on Ropart Asset Management.

TROY, Mich, August 16, 2012 – ViSalus today announced the appointment of Todd Goergen as Chief Strategy Officer. Mr. Goergen has served as Chairman of the ViSalus Board of Directors since Ropart Asset Management, of which he is Managing Partner, provided the original investment capital for ViSalus in 2006. Mr. Goergen is a member of ViSalus’ senior executive team and reports directly to Ryan Blair, Co-Founder and Chief Executive Officer of ViSalus.

“Having Todd join us as a member of our executive leadership team is of great benefit to ViSalus and brings our long-standing partnership full-circle,” stated Blair. “His leadership of our board for the past 6 years and his ongoing sound financial and operational counsel since the early days of ViSalus make him an ideal addition to our management team.”

Mr. Goergen has been Managing Partner of Ropart Asset Management (RAM), a private equity firm that invests directly in small to midsize companies, since 2001. RAM utilizes a flexible strategy, investing throughout the capital structure and in multiple industries, including Business Services, Healthcare Services, Consumer Products, Financial Services, and Software/Technology. Mr. Goergen was an Analyst / Associate in Mergers and Acquisitions at Donaldson, Lufkin & Jenrette from 1994-1999.

Mr. Goergen received a BA in Economics and Political Science from Wake Forest University. He resides in Greenwich, Connecticut with his wife and son.

Learn more about ViSalus at http://www.visalus.com and http://www.bodybyvi.com.

About ViSalus
Founded in 2005 with headquarters in Los Angeles, CA and Troy, MI, ViSalus is the company behind the Body by Vi™ Challenge, a 90-day health transformation platform. ViSalus champions personal victories and entrepreneurship through a social marketing model, premium products, and global community culture. ViSalus is majority-owned by Blyth, Inc. Visit www.Vi.com, or join us at facebook.com/visalus or on Twitter @visalus.

###

Contact: Katie Turner, ICR
katie.turner@icrinc.com, +1-646-277-1228

The post ViSalus Names Todd A. Goergen Chief Strategy Officer appeared first on Ropart Asset Management.